The present invention relates to a composition comprising esterase treated decaffeinated green coffee extract (HDGCE) for use in a method of improving cardiovascular endpoints such as endothelial function by enhancing flow mediated dilation in a subject, wherein the subject is administered an effective dose of HDGCE with an amount of 100-400 mg/day.

The invention relates to a method of preparing cannabis extracts, including shatter, budder and wax extracts. The extraction method can provide a high quality and pure extraction product of THC from cannabis plant material, as either a shatter, wax or budder end extraction product. The extracted product is free of polar cannabis plant material, chlorophyll and residual solvents, has a high concentrate of THC, and can be used for dabbing, vaping or smoking consumption by a user. Suitable solvents for the method are gases selected from the group consisting of propane, butane or iso-butane, and the preferred solvent is propane. A key step of the method of the present invention is recovering solvent under atmospheric vacuum and, therefore, obtaining an extraction product that is purified of solvent and has no solvent.

Provided are a pharmaceutical composition for preventing or treating diabetes and a method of preventing or treating diabetes in a subject by using the pharmaceutical composition, the pharmaceutical composition including a ginger extract, as an active ingredient, obtained by microwave irradiation, under pressure, of ginger, an extract thereof, or a combination thereof.

Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.

The invention relates to a method for producing standardised or quantified plant materials having reduced variance in phytonutrients, in particular from medicinal plants, using a mixture calculator.

In an aspect, the present disclosure provides a method for producing an extract composition by which polyphenols such as apigenin and/or essential oil components such as spiro-ether can be efficiently extracted from harvested herbaceous plants.

An aspect of the present disclosure is directed to a method for producing an extract composition, including processes (1) and (2) below: (1) applying an oxidative stress to a harvested herbaceous plant and preserving it; and (2) obtaining an extract from the herbaceous plant that has undergone the process (1).

The present invention relates to a composition for increasing the bioavailability and promoting the absorption of ginsenosides in a black ginseng extract.

The present invention provides compositions and products comprising a probiotic entrapped or encapsulated in a protein and carbohydrate matrix, sourced from a single non-fermented biomass and methods of producing thereof. In addition, the present invention provides methods for promoting health in a subject comprising administering a probiotic to a subject.

The present invention relates to an anti-influenza virus composition, a composition for treating respiratory diseases, and an anti-aging composition, each of which comprises a dark ginseng extract.

Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.